CONSTELLIUM SE current report, Q4 FY2017

Business Context and Reporting Period

This Form 6-K filing by Constellium N.V. (Constellium SE) covers the month of November 2017. The report discloses the completion of two significant capital raising transactions: an underwritten public offering of Class A ordinary shares (Equity Offering) and a private offering of senior unsecured notes (Notes Offering).

Key Financial Metrics and Transaction Details

  • Equity Offering: The Company sold 28,750,000 Class A ordinary shares, including 3,750,000 shares sold pursuant to the full exercise of the overallotment option by underwriters.
  • Offering Price: Shares were priced at $11.00 per Class A ordinary share.
  • Closing Date: The Equity Offering closed on November 3, 2017.
  • Notes Offering: The Company announced the pricing of U.S. dollar and euro-denominated senior unsecured notes on November 2, 2017.
  • Underwriters: Credit Suisse Securities (USA) LLC and Deutsche Bank Securities Inc. served as representatives.

Material Changes

The primary material change reported is the expansion of the Company's capital base through the issuance of new equity and debt securities. The filing confirms the validity of the issued shares via an opinion from Stibbe London N.V. dated November 3, 2017.

Guidance, Outlook, and Risks

The filing text does not provide specific financial guidance, management commentary on future outlook, or detailed risk factors beyond the standard legal disclaimers. The document explicitly states that the information contained herein is not incorporated by reference into any offering memorandum or registration statement unless expressly referenced.

Investor Verification Checklist

  • Verify the total gross proceeds from the Equity Offering (28,750,000 shares x $11.00).
  • Review the specific terms, interest rates, and maturity dates of the Notes Offering referenced in Exhibit 99.4.
  • Confirm the use of proceeds for both the equity and debt offerings in the Company's official press releases or prospectus supplements.
  • Check for any dilution impact on existing shareholders resulting from the 28,750,000 new shares issued.